Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study. Issue 5 (June 2023)

• Record Type: Journal Article
• Authors: Akazawa, Tsutomu; Inoue, Gen; Tanaka, Masahiro; Umehara, Tasuku; Nagai, Toshihiro; Oshita, Yusuke; Imura, Takayuki; Miyagi, Masayuki; Saito, Wataru; Sako, Kosuke; Nomura, Satoshi; Hiyama, Akihiko; Katoh, Hiroyuki; Sakai, Daisuke; Sato, Masato; Yoshida, Atsuhiro; Iinuma, Masahiro; Niki, Hisateru; Takaso, Masashi; Watanabe, Masahiko
• Is Part Of: Global spine journal. Volume 13:Issue 5(2023)
• Page Start: 1319
• Page End: 1324
• Publication Date: 2023-06
• Subjects: mirogabalin -- pregabalin -- neuropathic pain -- lumbar disease -- adverse event; Spine -- Diseases -- Periodicals; Spine -- Diseases -- Treatment -- Periodicals; Spine -- Abnormalities -- Periodicals; Spine -- Surgery -- Periodicals; 616.73
• DOI: 10.1177/21925682211031185
• Languages: English
• ISSNs: 2192-5682

Abstract

Study Design: Multicenter retrospective study. Objectives: To investigate adverse events (AEs) in patients with neuropathic pain related to lumbar disease who switched to mirogabalin from pregabalin. Methods: This study surveyed the records of 82 patients with peripheral neuropathic leg pain related to lumbar disease who switched to mirogabalin from pregabalin. We evaluated AEs associated with pregabalin and mirogabalin, the continuation rate of mirogabalin, and the pain-relieving effect at 4 weeks after switching from pregabalin to mirogabalin. We compared patients who switched due to lack of efficacy (LoE group) and patients who switched due to AEs (AE group). Results: The incidence rates of somnolence and dizziness with pregabalin were 12.2% and 14.6%, respectively, while the incidence rates with mirogabalin were reduced to 7.3% for somnolence and 4.9% for dizziness. The incidence of AEs with pregabalin was significantly higher in the AE group (LoE group: 11.1%, AE group 100%), especially for somnolence (LoE group: 3.2%, AE group: 47.1%) and dizziness (LoE group: 4.8%, AE: 52.9%). After switching, the incidences of AEs with mirogabalin were not significantly different between the 2 groups (LoE group: 15.9%, AE group: 23.5%), including for somnolence (LoE group: 7.9%, AE group: 5.9%) and dizziness (LoE group: 4.8%, AE group: 5.9%). There were no significant differences in continuation rate of mirogabalin or the pain-relieving effect between groups. Conclusions: The patients who experience somnolence and dizziness with pregabalin might be able to continue safely receiving treatment for their pain by switching to mirogabalin.